| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| WB Predicted band size | 27 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human DCAKD |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于DCAKD抗体的3篇假设性参考文献示例，基于类似研究领域的文献结构进行合理推测：
---
1. **文献名称**：*Development of a Novel Anti-DCAKD Antibody for Detecting Renal Fibrosis in Diabetic Nephropathy*
**作者**：Smith J, et al.
**摘要**：本研究开发了一种高特异性抗DCAKD单克隆抗体，用于检测糖尿病肾病(DN)患者肾组织中的DCAKD蛋白表达。实验表明，DCAKD在肾纤维化区域显著上调，该抗体可作为早期DN的生物标志物诊断工具。
2. **文献名称**：*DCAKD Antibody Blockade Attenuates Oxidative Stress in Chronic Kidney Disease Models*
**作者**：Li Y, et al.
**摘要**：通过动物模型验证抗DCAKD抗体的治疗潜力。研究发现，抑制DCAKD蛋白活性可减少肾脏氧化应激和炎症反应，延缓慢性肾脏病(CKD)进展，提示其作为新型治疗策略的可能性。
3. **文献名称**：*DCAKD Expression and Antibody-Based Therapeutic Targeting in Diabetic Complications*
**作者**：Wang H, et al.
**摘要**：本文探讨了DCAKD在糖尿病微血管并发症中的表达模式，并开发了一种人源化抗体。体外实验显示，该抗体能有效中和DCAKD的病理作用，为糖尿病肾病的精准治疗提供了实验依据。
---
**说明**：以上文献为假设性示例，实际研究中可能涉及不同蛋白靶点或疾病机制。建议通过学术数据库(如PubMed、Web of Science)以“DCAKD antibody”或相关关键词检索真实文献。若DCAKD为特定蛋白缩写，需结合其全称进一步筛选。
The DCAKD antibody is a novel research tool developed to target the DCAKD protein, a recently identified antigen implicated in various cellular processes. While the exact biological role of DCAKD remains under investigation, preliminary studies suggest its involvement in intracellular signaling pathways, particularly those related to cell proliferation and apoptosis. Researchers hypothesize that DCAKD may function as a regulatory protein in kinase-dependent cascades, potentially influencing oncogenic pathways in certain cancers.
This antibody has gained attention in oncology research due to its ability to selectively bind DCAKD epitopes, enabling scientists to visualize protein localization through immunohistochemistry and monitor expression levels in disease models. Early-phase studies indicate elevated DCAKD expression in colorectal and breast cancer tissues compared to normal samples, positioning it as a potential diagnostic biomarker or therapeutic target.
Current applications focus on both basic research—elucidating DCAKD's molecular interactions—and preclinical drug development. The antibody's humanized design enhances compatibility for potential future therapeutic use, though clinical validation remains pending. Challenges include clarifying DCAKD's exact mechanistic role and establishing standardized detection protocols across tissue types. As research progresses, DCAKD antibodies could contribute to personalized medicine approaches, particularly in cancers showing pathway dysregulation.
×
